Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana (M.M.H.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.X.Z.); Drug Metabolism and Pharmacokinetics, Bristol Myers Squibb, Princeton, New Jersey (J.R.C.); Development ADME, Novo Nordisk A/S, Måløv, Denmark (J.K.C.); Preclinical Development ADME, Merck & Co., Boston, Massachusetts (R.D.); PK Sciences/Global Biotransformation, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts (M.G.); DMPK, Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden (C.H.); Discovery Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Stevenage, United Kingdom (A.H.); Early Discovery Biochemistry, Genentech, Inc., South San Francisco, California (I.K.); Drug Metabolism and Pharmacokinetics, Bayer AG, Wuppertal, Germany (M.K., C.T.); Small Molecule Pharmaceutical Sciences, Genentech, Inc., South San Francisco, California (D.L.); Translational PK/PD and Investigative Toxicology, Janssen Research & Development, San Diego, California (K.W.); and Department of Drug Discovery Sciences, Discovery Science Technology Group, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach a.d. Riss, Germany (F.W.)